You are here

OV - Update Regarding Participation at Investor Events in Q4 2018

Investor news 

Hørsholm, Denmark and Cambridge, MA, US, November 5th, 2018 - Oncology Venture A/S ("Oncology Venture") today provided an update regarding when members of its senior management team are scheduled to make investor presentations during the fourth quarter of 2018. CEO Peter Buhl will present on two occasions: at the BIO-Europe conference in Copenhagen and at Sedermeradagen in Stockholm. CCO Claus Frisenberg Pedersen will present at a networking event held by Thamhaksa Company AB in Malmö. COO Ulla Hald Buhl will present at a member conference arranged by My Money Invest & Moneypenny in Copenhagen. Most events are free of charge. Please, see below for more details.

Investor meetings

Date and timeOrganiserPlaceRegistration
November 6th
11.30
BIO-EuropeBella Center
Center Blvd. 5,
2300 Copenhagen

Please register here to attend:
https://ebdgroup.knect365.com/bioeurope/
November 7th
16.35 - 17.00
Sedermera FondkommissionWaterfront Congress Center
Nils Ericsons Plan 4
111 64 Stockholm

Please register here to attend: https://www.sedermera.se/da/evenemang/2018-11-07/sedermeradagen-stockholm-2018
November 7th 
9.45 - 10.30
Thamhaksa Company ABMAQS Advokatbyrå,
Gibraltargatan 7,
211 18 Malmö

To attend, RSVP to Veeradeth Thamhaksa, veeradeth@thamhaksa.com by October 26th to confirm your attendance.
    
November 10th
12.45
Moneypenny & My Money InvestMetropol,
Kronprinsesse Sofies Vej 35,
2000 Frederiksberg
Please register here to attend:
https://www.eventbrite.com/e/moneypenny-medlemskonference-kbh-tickets-50044802351
    
    

For further information, please contact:

For investor inquiries
Ulla Hald Buhl, IR & Communication
E-mail: uhb@oncologyventure.com
Telephone +45 21 70 10 49
For media inquiries
Thomas Pedersen, Carrotize - Your Communications
E-mail: tsp@carrotize.com
Telephone +45 60 62 93 90

About Oncology Venture A/S
Oncology Venture A/S is engaged in the research and development of anti-cancer drugs via its wholly-owned subsidiary, Oncology Venture Product Development ApS. Oncology Venture uses Drug Response Prediction - DRP® -to significantly increase the probability of success in clinical trials. DRP® has proven its ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients in 29 out of 37 clinical studies that were examined and is currently demonstrating promising results in an ongoing phase 2 study prospectively using LiPlaCis and its DRP® to track, match and treat patients with metastatic breast cancer. The DRP® alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients' tumors genes are first screened, and only the patients most likely to respond to the treatment will be treated. Via a more well-defined patient group, risks and costs are reduced while the development process becomes more efficient.

The current OV product portfolio includes: LiPlaCis®, a liposomal formulation of cisplatin in an ongoing Phase 2 trial for breast and prostate cancer; 2X-121 a PARP inhibitor in an ongoing Phase 2 for breast cancer; dovitinib, which will enter Phase 2 trials for indications dependent on further Dovitinib-DRP retrospective/prospective analysis of studies completed by Novartis. 2X-111, a liposomal formulation of doxorubicin under manufacturing for Phase 2 in breast cancer; irofulven, a Phase 2 is ongoing for prostate cancer; and APO010, an immuno-oncology product in Phase 1/2 for multiple myeloma. 

Oncology Venture has spun out two companies as Special Purpose Vehicles: Oncology Venture U.S. Inc. (previously 2X Oncology Inc.), a US-based precision medicine company focusing on developing 2X-121 and 2X-111, and OV-SPV 2, a Danish company that will test and develop dovitinib. Oncology Venture A/S has an ownership of 92% in Oncology Venture US and 55% of dovitinib with an opportunity to acquire further 30%. 

Learn more at oncologyventure.com

Follow us on social media:

Facebook: https://www.facebook.com/oncologyventure/
LinkedIn: https://www.linkedin.com/company/oncology-venture/
Twitter: https://twitter.com/OncologyVenture

DRP® is a registered trademark of Oncology Venture A/S.

Forward-looking statements
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV's control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV's plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.

Certified Adviser: Sedermera Fondkommission, Norra Vallgatan 64, 211 22, Malmö, Sverige

Attachment

Thursday, November 8, 2018 - 19:59

More Headlines

Zulresso May Alleviate Symptoms for Thousands of Women
Developed for Tumors Resistant to Other TKIs
New Drug Reduces Infection in Chemotherapy Patients
Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV
Unique Bio-Identical Hormone Therapy for Treatment of Hot Flashes
High-Tech “Nightwatch” is Capable of Detecting 85 Percent of Severe Night-Time Epileptic Seizures
Combination of Buprenorphine and Samidorphan Targets Opioid System Safely and Effectively
Prevents Harmful Effects of Chemotherapy